SIRAKOSS is an innovative medical device company based in Scotland, specializing in the development of synthetic bone graft substitutes for various applications such as trauma, spine, craniomaxillofacial, and dental procedures. Their proprietary MaxSi(TM) Graft technology offers efficient treatment for spinal fusions and bone defects. By fusing bones together, the company's technology helps correct congenital or degenerative conditions, enabling patients to recover quickly and lead a healthy lifestyle. SIRAKOSS provides bone grafting solutions to surgeons, with their first formulation, Osteo3, being a unique nanosynthetic bone graft substitute composed of novel inorganic granules. Osteo3 has demonstrated significantly improved healing in challenging models, supporting its potential for achieving rapid patient recovery reliably. SIRAKOSS places a strong emphasis on developing robust clinical data to validate the efficacy of their products.